Guidelines on the Prevention and Control of Tuberculosis in Ireland

More documents

Recommendations

Info

<strong>Guidelines</strong> on the Prevention and Control of Tuberculosis in Ireland 2010HSE/HPSC(348) Page KR, Chaisson RE, Godfrey-Faussett P. Tuberculosis HIV Co-infection: Epidemiology, ClinicalAspects, and Interventions. Tuberculosis: a comprehensive international approach. Third ed. NewYork, USA: Informa Healthcare; 2006. 371-416.(349) Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of themanifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virusinfection. American Journal of Respiratory and Critical Care Medicine 1993; 148(5):1292-1297.(350) Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS et al. Effect of Mycobacteriumtuberculosis on HIV replication: role of immune activation. Journal of immunology 1996;157(3):1271-1278.(351) Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in-vitro induction of humanimmunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected personsby recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effectsof endogenous interleukin-2 and proinflammatory and anti-inflammatory cytokines. Journal ofInfectious Diseases 1998; 177(5):1332-1338.(352) Mayanja-Kizza H, Johnson JL, Hirsch CS, Peters P, Surewicz K, Nalugwa G et al. Macrophageactivatingcytokines in human immunodeficiency virus type-1 and uninfected patients withpulmonary tuberculosis. Journal of Infectious Diseases 2001; 183(12):1805-1809.(353) Batungwanayo J, Taelman H, Bogaerts J, Allen S, Van dePerre P. Pulmonary tuberculosis inKigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographicpresentation. American Review of Respiratory Disease 1992; 146:53-56.(354) Klein NC, Duncanson FP, Lennox TH, Pitta A, Cohen SC, Wormser GP. Use of mycobacterial smearsin the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. Chest 1989; 95:1190-1192.(355) Hsieh SM, Hung CC, Chen MY, Hsueh PR, Chang SC, Luh KT. The role of tissue studies in facilitatingearly initiation of antimycobacterial treatment in AIDS patients with disseminated Mycobacterialdisease. International Journal of Tuberculosis and Lung Disease 1999; 3:521-527.(356) Relkin F, Aranda CP, Garay DM, Smith R, Berkowitz KA, Rom WN. Pleural tuberculosis and HIVinfection. Chest 1994; 105:1338-1341.(357) Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among personsinfected with human immunodeficiency virus and seronegative controls. Clinical Infectious Diseases1992; 15:601-605.(358) Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. NewEngland Journal of Medicine 1999; 340(5):367-373.(359) Stout JE, Ratard R, Southwick KL, Hamilton CD. Epidemiology of human immunodeficiency testingamong patients with tuberculosis in North Carolina. Southern Medical Journal 2002; 95(2):231-238.(360) Bartlett JG, Gallant JE. Medical management of HIV infection 2001-2002. Baltimore: Johns HopkinsUniversity, Division of Infectious Disease; 2001.(361) Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA et al. Tuberculin andanergy testing in HIV-sero-positive and HIV sero-negative persons. Pulmonary complications of HIVinfection study group. Annals of Internal Medicine 1993; 119:-185.(362) Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis inSouth African children with a T-cell based assay: a prospective cohort study. Lancet 2004; 364:2196-2203.(363) Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL et al. A controlled trial of isoniazidin person with anergy and human immunodeficiency virus infection who are at high risk fortuberculosis. New England Journal of Medicine 1997; 337:315-320.-153-
<strong>Guidelines</strong> on the Prevention and Control of Tuberculosis in Ireland 2010HSE/HPSC(364) Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J et al. Isoniazid preventive therapy inhuman immunodeficiency virus-infected persons. Long-term effect on development of tuberculosisand survival. Archives of Internal Medicine 1997; 157:1729-1734.(365) Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P et al. A trial of three regimensto prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. NewEngland Journal of Medicine 1997; 337:80180-808.(366) Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus,homelessness, and the decline of tuberculosis control programs. American Review of RespiratoryDisease 1991; 144:745-749.(367) Centers for Disease Control and Prevention. Emerging infectious diseases. Tuberculosis morbidity -United States 1992. Morbidity and Mortality Weekly Report 1993; 42:696.(368) Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City- turning the tide.New England Journal of Medicine 2007; 333:229-233.(369) Centers for Disease Control and Prevention. <strong>Guidelines</strong> for preventing opportunistic infectionsamong HIV-infected persons - 2002. Morbidity and Mortality Weekly Report 2002; 51(RR-8):1-17.(370) Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosisin South Africa: a cohort study. Lancet 2002; 359:2059-2064.(371) Jones BE, Young SM, Antoniskis D, Davidson PT, Barnes PF. Relationship of the manifestations oftuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. AmericanReview of Respiratory Disease 1993; 148:1292-1297.(372) Santoro-Lopes G, de Pinho AM, Harrison LH, Schecter GF. Reduced risk of tuberculosis amongBrazilian patients with advanced human immunodeficiency virus infection treated with highly activeantiretroviral therapy. Clinical Infectious Diseases 2002; 34:543-546.(373) Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. Factors associated withan increased case-fatality rate in HIV-infected and non-infected South African gold miners withpulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2000; 4:705-712.(374) Murray J, Sonnenberg P, Shearer SC, Godfrey-Fausset P. Human immunodeficiency virus and theoutcome of treatment for new and recurrent pulmonary tuberculosis in African patients. AmericanJournal of Critical Care Medicine 1999; 159:733-740.(375) Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R et al. Cohort of humanimmunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early(6-month) mortality. American Review of Respiratory Disease 1992; 146:849-854.(376) Carvalho AC, DeRiemer K, Nunes ZB, Martins M, Comelli M, Marinoni A et al. Transmission ofMycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. American Journal ofRespiratory and Critical Care Medicine 2001; 164(12):2166-2171.(377) Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiencyvirus type 1 on infectiousness of tuberculosis: a meta-analysis. Clinical Infectious Diseases 2001;33(11):1922-1930.(378) Iseman D. Tuberculosis in relation to HIV and AIDS. A clinician’s guide to tuberculosis. Philadelphia:Lipincott Williams and Wilkins; 2000. 199-252.(379) The interdepartmental Working Group on Tuberculosis. The prevention and control of tuberculosisin the United Kingdom: UK guidance on the prevention and control of: 1 HIV-1 related tuberculosis;2 drug resistant including multiple drug-resistant tuberculosis. 1998. Department of Health, UK.(380) Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H et al. A diarylquinolinedrug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307(5707):223-227.-154-
Page 2 and 3:
Guidelines on the
Page 4 and 5:
Guidelines on the
Page 6 and 7:
Guidelines on the
Page 8 and 9:
Guidelines on the
Page 10 and 11:
Guidelines on the
Page 12 and 13:
Guidelines on the
Page 14 and 15:
Guidelines on the
Page 16 and 17:
Guidelines on the
Page 18 and 19:
Guidelines on the
Page 20 and 21:
Guidelines on the
Page 22 and 23:
Guidelines on the
Page 24 and 25:
Guidelines on the
Page 26 and 27:
Guidelines on the
Page 28 and 29:
Guidelines on the
Page 30 and 31:
Guidelines on the
Page 32 and 33:
Guidelines on the
Page 34 and 35:
Guidelines on the
Page 36 and 37:
Guidelines on the
Page 38 and 39:
Guidelines on the
Page 40 and 41:
Guidelines on the
Page 42 and 43:
Guidelines on the
Page 44 and 45:
Guidelines on the
Page 46 and 47:
Guidelines on the
Page 48 and 49:
Guidelines on the
Page 50 and 51:
Guidelines on the
Page 52 and 53:
Guidelines on the
Page 54 and 55:
BGuidelines on the
Page 56 and 57:
Guidelines on the
Page 58 and 59:
Guidelines on the
Page 60 and 61:
Guidelines on the
Page 62 and 63:
Guidelines on the
Page 64 and 65:
Guidelines on the
Page 66 and 67:
Guidelines on the
Page 68 and 69:
Guidelines on the
Page 70 and 71:
1♦Guidelines on
Page 72 and 73:
Guidelines on the
Page 74 and 75:
Guidelines on the
Page 76 and 77:
Guidelines on the
Page 78 and 79:
Guidelines on the
Page 80 and 81:
Guidelines on the
Page 82 and 83:
Guidelines on the
Page 84 and 85:
Guidelines on the
Page 86 and 87:
Guidelines on the
Page 88 and 89:
Guidelines on the
Page 90 and 91:
Guidelines on the
Page 92 and 93:
Guidelines on the
Page 94 and 95:
Guidelines on the
Page 96 and 97:
Guidelines on the
Page 98 and 99:
Figure 6.1Patient placement for Pul
Page 100 and 101:
Guidelines on the
Page 102 and 103:
Guidelines on the
Page 104 and 105:
Guidelines on the
Page 106 and 107:
Guidelines on the
Page 108 and 109:
Guidelines on the
Page 110 and 111:
Guidelines on the
Page 112 and 113:
Guidelines on the
Page 114 and 115:
Guidelines on the
Page 116 and 117:
Guidelines on the
Page 118 and 119:
Guidelines on the
Page 120 and 121:
Guidelines on the
Page 122 and 123: Guidelines on the
Page 218: 25-27 Middle Gardiner Street Dublin
show all

Guidelines on the Prevention and Control of Tuberculosis in Ireland

Create successful ePaper yourself

Delete template?

Save as template?